Rigel Pharmaceuticals Inc (RIGL): Shareholders' Equity
$391.48M
As of 2025-12-31
$425.42M
As of 2026-06-30
+63.0%
5-year compound annual growth
+15.7%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $391.48M | n/m | 2026-03-03, Balance as of period end |
| 2024-12-31 | $3.29M | n/m | 2026-03-03, Balance as of period end |
| 2023-12-31 | -$28.64M | n/m | 2026-03-03, Balance as of period end |
| 2022-12-31 | -$13.62M | n/m | 2025-03-04, Balance as of period end |
| 2021-12-31 | $30.37M | -10.7% | 2024-03-05, Balance as of period end |
| 2020-12-31 | $34.03M | -36.8% | 2023-03-07, Balance as of period end |
| 2019-12-31 | $53.81M | -51.0% | 2022-03-01, Balance as of period end |
| 2018-12-31 | $109.88M | +9.2% | 2021-03-02, Balance as of period end |
| 2017-12-31 | $100.65M | +82.9% | 2020-02-27, Balance as of period end |
| 2016-12-31 | $55.03M | -39.8% | 2019-02-28, Balance as of period end |
| 2015-12-31 | $91.38M | -28.7% | 2018-03-06, Balance as of period end |
| 2014-12-31 | $128.25M | -38.4% | 2017-03-07, Balance as of period end |
| 2013-12-31 | $208.25M | -28.0% | 2016-03-08, Balance as of period end |
| 2012-12-31 | $289.10M | +22.4% | 2015-03-03, Balance as of period end |
| 2011-12-31 | $236.15M | +42.1% | 2014-03-04, Balance as of period end |
| 2010-12-31 | $166.13M | +51.2% | 2013-03-05, Balance as of period end |
| 2009-12-31 | $109.87M | n/a | 2012-03-06, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $391.48M | n/m |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $484.65M | +58.7% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $166.95M | -3.7% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $64.63M | -77.6% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $493.40M | +40.0% |
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $478.56M | +17.0% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $327.19M | -39.2% |
| Oruka Therapeutics, Inc. (ORKA) | 2025-12-31 | $471.93M | +23.5% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $139.07M | +540.0% |
Compare RIGL, RAPP, ARDX, SNDX side by side · Screen every company in Pharmaceutical Preparations ↗